Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database.

Authors

Aarti A Patel, Shannon Ferrante, Myrlene Sanon, Sumesh Kachroo

Published in

Advances in therapy. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited.
The retrospective observational study was conducted using Optum's de-identified Clinformatics^® Data Mart Database (Optum^® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity.
A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals.
The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.

PMID:
42423953
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.